A Phase 2 interventional study of Deucravacitinib in Crohn Disease and Ulcerative Colitis, sponsored by Bristol-Myers Squibb. Completed at 43 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-24.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Crohn Disease by Bristol-Myers Squibb — none open to participants now, none under way, none of them phase 3. Crohn Disease · Bristol-Myers Squibb.
Among the 16 studies in Crohn Disease by Bristol-Myers Squibb, this one is the 12th largest by enrollment, is the only one that started in 2021, is one of 6 in phase 2, and was the 15th registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →None of the 16 studies in Crohn Disease by Bristol-Myers Squibb is open now. The open studies under Crohn Disease, anywhere →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 9
First in 2002; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 67 is close to the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 180 across the 16 interventional studies. Of the 15 that completed or were terminated, 11 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Crohn Disease by Bristol-Myers Squibb, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the long-term safety and efficacy of Deucravacitinib in participants who have previously been enrolled in a Deucravacitinib Phase 2 study for moderate to severe Crohn's disease or moderate to severe Ulcerative Colitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Drug: Deucravacitinib
Specified dose on specified days
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
Number of participants experiencing AEs, SAEs, AEs leading to study discontinuation, and AEs of interest (AEIs). An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. SAEs is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization; results significant disability; or is a congenital anomaly/birth defect. TEAEs are defined as AEs with an onset date on or after the first dose of study treatment up to 30 days after the last dose of study treatment in the study, or if a pre-existing condition worsens in severity or becomes serious after receiving the first dose of study treatment
Time frame: From first dose to 30 days post last dose (Up to 110 weeks)
Number of Participants With Laboratory Abnormalities
Number of participants experiencing abnormalities in laboratory testing including chemistry, hematology, and renal.
Time frame: From first dose to 30 days post last dose (Up to 110 weeks)
Number of Participants With Electrocardiogram (ECG) Abnormalities
Time frame: From first dose to 30 days post last dose (Up to 110 weeks)
Number of Participants With Vital Signs Abnormalities
Time frame: From first dose to 30 days post last dose (Up to 110 weeks)
Change From Baseline in Laboratory Parameters
Change from baseline in laboratory parameters including lipid profile, chemistry liver function, chemistry (other), and chemistry renal function
Time frame: Baseline, Week 12, Week 108
Change From Baseline in Electrocardiogram (ECG) Parameters - ECG Mean Heart Rate
Changes from IM011077 study baseline in electrocardiogram (ECG) parameters - ECG mean heart rate
Time frame: Baseline, Week 48, Week 96
Change From Baseline in Electrocardiogram (ECG) Parameters
Changes from IM011077 study baseline in electrocardiogram (ECG) parameters
Time frame: Baseline, Week 48, Week 96
Change From Baseline in Vital Signs Parameters - Heart Rate
Changes from IM011077 study baseline in vital signs parameters - heart rate
Time frame: Baseline, Week 12, Week 108
Change From Baseline in Vital Signs Parameters
Changes from IM011077 study baseline in vital signs parameters
Time frame: Baseline, Week 12, Week 108
| Milestone | Crohn's Disease | Ulcerative Colitis |
|---|---|---|
| Started | 26 | 41 |
| Completed | 24 | 41 |
| Not completed | 2 | 0 |
| Milestone | Crohn's Disease | Ulcerative Colitis |
|---|---|---|
| Started | 24 | 41 |
| Completed | 0 | 0 |
| Not completed | 24 | 41 |
| Withdrew: Other reasons | 3 | 1 |
| Withdrew: Administrative reasons by sponsor | 17 | 33 |
| Withdrew: Withdrawal by subject | 2 | 6 |
| Withdrew: Adverse event | 2 | 1 |
Number of participants experiencing AEs, SAEs, AEs leading to study discontinuation, and AEs of interest (AEIs). An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. SAEs is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization; results significant disability; or is a congenital anomaly/birth defect. TEAEs are defined as AEs with an onset date on or after the first dose of study treatment up to 30 days after the last dose of study treatment in the study, or if a pre-existing condition worsens in severity or becomes serious after receiving the first dose of study treatment
| Participants | Crohn's Disease | Ulcerative Colitis |
|---|---|---|
| TEAEs | 18 | 19 |
| TESAEs | 2 | 2 |
| TEAEs leading to study discontinuation | 1 | 1 |
| AEs of Interest - Skin-related events | 0 | 2 |
| AEs of Interest - Creatine Kinase events | 2 | 3 |
Number of participants experiencing abnormalities in laboratory testing including chemistry, hematology, and renal.
| Participants | Crohn's Disease | Ulcerative Colitis |
|---|---|---|
| Sodium < 130 or > 150 MEQ/L (MMOL/L) | 0 | 0 |
| Potassium < 3 or > 5.5 MEQ/L (MMOL/L) | 0 | 1 |
| Calcium > 12.5 MG/DL | 0 | 0 |
| Fasting Serum Glucose < 50 MG/DL or > 250 MG/DL | 0 | 0 |
| Albumin < 2.0 G/DL | 0 | 0 |
| Creatine Kinase > 10xupper limit of normal | 0 | 0 |
| Hemoglobin < 7.0 G/DL or > 30% reduction from baseline | 0 | 0 |
| Hematocrit < 20% or 30% reduction from baseline | 0 | 0 |
| White Blood Cell Count < 1.5 x 10^9/L or > 35 x 10^9/L | 0 | 0 |
| Lymphocyte Count < 0.5 x 10^9/L | 0 | 0 |
| Neutrophil Count < 0.75 x 10^9/L | 0 | 0 |
| Platelet Count < 75 x 10^9/L or > 999 x 10^9/L | 0 | 0 |
| Serum Creatinine Increase > 50% and > 44.2 UMOL/L | 0 | 0 |
| Participants | Crohn's Disease | Ulcerative Colitis |
|---|---|---|
| QTCF (MSEC) 450 - < 480 | 1 | 0 |
| QTCF (MSEC) 480 - < 500 | 0 | 1 |
| QTCF (MSEC) >= 500 | 0 | 0 |
| 30 < CHANGE FROM IM011077 STUDY BASELINE <= 60 MSEC | 3 | 0 |
| CHANGE FROM IM011077 STUDY BASELINE > 60 MSEC | 3 | 5 |
| PRAG (MSEC) P WAVE AND R WAVE (PR) INTERVAL >= 240 MSEC | 0 | 0 |
| QRSAG(MSEC) QRS INTERVAL >= 200 MSEC | 0 | 0 |
| Participants | Crohn's Disease | Ulcerative Colitis |
|---|---|---|
| HEART RATE (BEATS/MIN): VALUE > 100 AND CHANGE FROM IM011077 STUDY BASELINE > 30 | 1 | 1 |
| HEART RATE (BEATS/MIN): VALUE < 55 AND CHANGE FROM IM011077 STUDY BASELINE < -15 | 1 | 0 |
| SYSTOLIC BLOOD PRESSURE (MMHG): VALUE > 140 AND CHANGE FROM IM011077 STUDY BASELINE > 20 | 3 | 5 |
| SYSTOLIC BLOOD PRESSURE (MMHG): VALUE < 90 AND CHANGE FROM IM011077 STUDY BASELINE < -20 | 0 | 0 |
| DIASTOLIC BLOOD PRESSURE (MMHG): VALUE > 90 AND CHANGE FROM IM011077 STUDY BASELINE > 10 | 3 | 5 |
| DIASTOLIC BLOOD PRESSURE (MMHG): VALUE < 55 AND CHANGE FROM IM011077 STUDY BASELINE < -10 | 0 | 0 |
Change from baseline in laboratory parameters including lipid profile, chemistry liver function, chemistry (other), and chemistry renal function
| mg/dL | Crohn's Disease | Ulcerative Colitis |
|---|---|---|
| Cholesterol, Fasting Week 12 | 10.20 ± 7.207 | -9.17 ± 4.629 |
| Cholesterol, Fasting Week 108 | -12.00 ± NA | — |
| HDL Cholesterol, Fasting Week 12 | -0.75 ± 3.400 | -0.83 ± 2.626 |
| HDL Cholesterol, Fasting Week 108 | 0.00 ± NA | — |
| LDL Cholesterol, Fasting Week 12 | 4.75 ± 4.270 | -6.50 ± 4.689 |
| LDL Cholesterol, Fasting Week 108 | 1.00 ± NA | — |
| Triglycerides, Fasting Week 12 | 2.3 ± 11.31 | 3.2 ± 4.78 |
| Triglycerides, Fasting Week 108 | -62.0 ± NA | — |
| Bilirubin, Week 12 | 0.0650 ± 0.05028 | 0.0043 ± 0.03566 |
| Bilirubin, Week 108 | -0.1000 ± 0.00000 | — |
| Glucose, Fasting Serum Week 12 | 1.75 ± 0.946 | 0.80 ± 1.114 |
| Glucose, Fasting Serum Week 108 | 29.00 ± NA | — |
| Calcium, Week 12 | 0.152 ± 0.0915 | 0.041 ± 0.0612 |
| Calcium, Week 108 | 0.350 ± 0.1500 | — |
| Creatinine, Week 12 | -0.008 ± 0.0182 | 0.004 ± 0.0153 |
| Creatinine, Week 108 | 0.080 ± 0.0100 | — |
| Phosphate, Week 12 | 0.153 ± 0.0893 | 0.019 ± 0.1198 |
| Phosphate, Week 108 | -0.150 ± 0.1500 | — |
| Urea Nitrogen, Week 12 | -0.269 ± 1.0631 | 0.511 ± 0.5902 |
| Urea Nitrogen, Week 108 | 5.500 ± 0.5000 | — |
Changes from IM011077 study baseline in electrocardiogram (ECG) parameters - ECG mean heart rate
| beats/min | Crohn's Disease | Ulcerative Colitis |
|---|---|---|
| ECG Mean Heart Rate, Week 48 | -1.4 ± 9.21 | 2.6 ± 12.76 |
| ECG Mean Heart Rate, Week 96 | -1.0 ± 11.27 | -1.0 ± NA |
Changes from IM011077 study baseline in electrocardiogram (ECG) parameters
| msec | Crohn's Disease | Ulcerative Colitis |
|---|---|---|
| PR Interval, Aggregate, Week 48 | 9.1 ± 20.62 | -2.4 ± 22.65 |
| PR Interval, Aggregate, Week 96 | 14.7 ± 16.56 | -22.0 ± NA |
| QRS Duration, Aggregate, Week 48 | -1.2 ± 8.47 | -0.9 ± 8.53 |
| QRS Duration, Aggregate, Week 96 | -9.3 ± 2.89 | 0.0 ± NA |
| QT Interval, Aggregate, Week 48 | 18.6 ± 30.33 | 7.6 ± 40.35 |
| QT Interval, Aggregate, Week 96 | 27.0 ± 62.55 | 96.0 ± NA |
| QTcB Interval, Aggregate, Week 48 | -2.3 ± 21.78 | 7.7 ± 19.41 |
| QTcF Interval, Aggregate, Week 48 | -20.6388 ± 197.49472 | 31.1621 ± 141.14597 |
| QTcF Interval, Aggregate, Week 96 | -86.9797 ± 198.61888 | 101.0000 ± NA |
Changes from IM011077 study baseline in vital signs parameters - heart rate
| beats/min | Crohn's Disease | Ulcerative Colitis |
|---|---|---|
| Heart Rate Week 12 | 3.6 ± 11.89 | 0.9 ± 10.71 |
| Heart Rate Week 108 | 1.0 ± NA | — |
Changes from IM011077 study baseline in vital signs parameters
| mmHg | Crohn's Disease | Ulcerative Colitis |
|---|---|---|
| Systolic Blood Pressure Week 12 | 3.8 ± 11.56 | 3.8 ± 13.62 |
| Systolic Blood Pressure Week 108 | 4.0 ± NA | — |
| Diastolic Blood Pressure Week 12 | 0.3 ± 7.82 | -1.3 ± 7.38 |
| Diastolic Blood Pressure Week 108 | 9.0 ± NA | — |
Collected over SAEs and AEs are assessed from first dose to 30 days post last dose (Up to 110 weeks). Participants were assessed for all-cause mortality from their first dose to study completion (Up to 120 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CROHN'S DISEASE | 0/26 (0%) | 2/24 (8.3%) | 12/24 (50%) |
| ULCERATIVE COLITIS | 0/41 (0%) | 2/41 (4.9%) | 13/41 (31.7%) |
| Event | CROHN'S DISEASE | ULCERATIVE COLITIS |
|---|---|---|
| Small intestinal obstructionGastrointestinal disorders | 1/24 | 0/41 |
| PneumoniaInfections and infestations | 1/24 | 0/41 |
| SepsisInfections and infestations | 1/24 | 0/41 |
| Urinary tract infectionInfections and infestations | 1/24 | 0/41 |
| Cardiac failure chronicCardiac disorders | 0/24 | 1/41 |
| Colitis ulcerativeGastrointestinal disorders | 0/24 | 1/41 |
| General physical health deteriorationGeneral disorders | 0/24 | 1/41 |
| Procedural pneumothoraxInjury, poisoning and procedural complications | 0/24 | 1/41 |
| Event | CROHN'S DISEASE | ULCERATIVE COLITIS |
|---|---|---|
| COVID-19Infections and infestations | 6/24 | 3/41 |
| NasopharyngitisInfections and infestations | 3/24 | 0/41 |
| PneumoniaInfections and infestations | 3/24 | 0/41 |
| Upper respiratory tract infectionInfections and infestations | 2/24 | 5/41 |
| Mouth ulcerationGastrointestinal disorders | 2/24 | 1/41 |
| PyrexiaGeneral disorders | 2/24 | 1/41 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/24 | 1/41 |
| Colitis ulcerativeGastrointestinal disorders | 0/24 | 3/41 |
| TonsillitisInfections and infestations | 0/24 | 3/41 |
| DepressionPsychiatric disorders | 0/24 | 3/41 |
| Age, Continuous(Years) | Crohn's Disease | Ulcerative Colitis | Total |
|---|---|---|---|
| Mean | 38.7 ± 14.08 | 44.3 ± 15.70 | 42.2 ± 15.24 |
| Sex: Female, Male(Participants) | Crohn's Disease | Ulcerative Colitis | Total |
|---|---|---|---|
| Female | 10 | 19 | 29 |
| Male | 16 | 22 | 38 |
| Ethnicity (NIH/OMB)(Participants) | Crohn's Disease | Ulcerative Colitis | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 |
| Not Hispanic or Latino | 21 | 35 | 56 |
| Unknown or Not Reported | 5 | 5 | 10 |
| Race/Ethnicity, Customized(Participants) | Crohn's Disease | Ulcerative Colitis | Total |
|---|---|---|---|
| White | 21 | 38 | 59 |
| Black or African American | 1 | 0 | 1 |
| Asian | 2 | 0 | 2 |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Other | 0 | 0 | 0 |
| Asian Indian | 0 | 0 | 0 |
| Chinese | 2 | 0 | 2 |
| Japanese | 0 | 3 | 3 |
| Asian Other | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2021 to primary completion in Aug 2023, 27 months.
Results were first posted in Sep 2024, 1 year after primary completion.
Of 56 industry-sponsored phase 2 interventional studies under Crohn Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 27 months is below that.
Counting every sponsor, half of 83 studies reached it within 34 months; a quarter within 23 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Deucravacitinib